GSK plc (NYSE:GSK) has a beta value of 0.64 and has seen 5.3 million shares traded in the last trading session. The company, currently valued at $62.06B, closed the last trade at $30.49 per share which meant it lost -$0.29 on the day or -0.94% during that session. The GSK stock price is -56.84% off its 52-week high price of $47.82 and 0.0% above the 52-week low of $30.49. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.18 million shares traded. The 3-month trading volume is 6.35 million shares.
The consensus among analysts is that GSK plc (GSK) is an Overweight stock at the moment, with a recommendation rating of 2.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 15 out of 22 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $0.89.
GSK plc (NYSE:GSK) trade information
Sporting -0.94% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 09/20/22 when the GSK stock price touched $30.49 or saw a rise of 3.42%. Year-to-date, GSK plc shares have moved -32.08%, while the 5-day performance has seen it change -3.60%. Over the past 30 days, the shares of GSK plc (NYSE:GSK) have changed -10.48%. Short interest in the company has seen 5.57 million shares shorted with days to cover at 1.28.
Wall Street analysts have a consensus price target for the stock at $41.51, which means that the shares’ value could jump 26.55% from current levels. The projected low price target is $33.12 while the price target rests at a high of $59.54. In that case, then, we find that the current price level is -95.28% off the targeted high while a plunge would see the stock gain -8.63% from current levels.
GSK plc (GSK) estimates and forecasts
Figures show that GSK plc shares have underperformed across the wider relevant industry. The company’s shares have lost -30.09% over the past 6 months, with this year growth rate of -16.97%, compared to 1.40% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are -9.20% and -17.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be -17.50%.
2 analysts offering their estimates for the company have set an average revenue estimate of $9.17 billion for the current quarter. 2 have an estimated revenue figure of $10.06 billion for the next quarter concluding in Sep 2022.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 36.00% over the past 5 years. Earnings growth for 2022 is a modest -24.10% while over the next 5 years, the company’s earnings are expected to increase by 10.30%.
GSK plc is expected to release its next earnings report between February 01 and February 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.85 at a share yield of 6.08%. The company’s dividend yield has gone up over the past 12 months.
GSK plc (NYSE:GSK)’s Major holders
Insiders own 0.03% of the company shares, while shares held by institutions stand at 10.81% with a share float percentage of 10.81%. Investors are also buoyed by the number of investors in a company, with GSK plc having a total of 1,039 institutions that hold shares in the company. The top two institutional holders are Dodge & Cox Inc with over 85.75 million shares worth more than $4.67 billion. As of Mar 30, 2022, Dodge & Cox Inc held 4.22% of shares outstanding.
The other major institutional holder is Capital International Investors, with the holding of over 19.1 million shares as of Mar 30, 2022. The firm’s total holdings are worth over $1.04 billion and represent 0.94% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Dodge & Cox Stock Fund and American Mutual Fund Inc. As of Jun 29, 2022, the former fund manager holds about 2.53% shares in the company for having 51.38 million shares of worth $2.8 billion while later fund manager owns 14.1 million shares of worth $767.47 million as of Jun 29, 2022, which makes it owner of about 0.69% of company’s outstanding stock.